

*The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.*

**MINUTES FROM THE ANNUAL  
GENERAL MEETING HELD IN  
ALLIGATOR BIOSCIENCE AB, REG. NO.  
556597-8201, ON 6 MAY 2026 AT  
10.00 A.M. IN LUND.**

**1. OPENING OF THE MEETING**

Lawyer Ola Grahn opened the meeting on behalf of the board.

**2. ELECTION OF CHAIRMAN OF THE MEETING**

It was resolved to elect lawyer Ola Grahn as Chairman of the meeting. The Chairman of the meeting should keep the minutes.

It was furthermore resolved that guests were allowed to attend the meeting as audience.

**3. PREPARATION AND APPROVAL OF THE REGISTER OF VOTERS**

A list of present shareholders, proxies, advisors and other present persons in accordance with **Schedule 1** was prepared.

The above mentioned list in accordance with Schedule 1 was approved as the voting list at the meeting.

**4. ELECTION OF TWO PERSONS TO CONFIRM THE MINUTES**

It was resolved that two persons should confirm the minutes. Anna Stéen and Claes Åkerbladh were elected as such persons to confirm the minutes.

**5. APPROVAL OF THE AGENDA**

It was resolved to approve the agenda in accordance with the proposal from the board of directors as set out in the notice to attend the annual general meeting, **Schedule 2**.

**6. DETERMINATION AS TO WHETHER THE MEETING HAS BEEN DULY CONVENED**

It was noted that the notice to attend the annual general meeting, in accordance with the Articles of Association and the provisions of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)), had been inserted in the Swedish Official Gazette (Sw. Post- och Inrikes Tidningar) on 2 April 2026, that the notice to attend the annual general meeting has been available at the company's website since 30 March 2026, and that the advert regarding the notice to attend the annual general meeting had been inserted in Dagens Industri on 2 April 2026.

The meeting was declared to be duly convened.

**7. PRESENTATION BY THE CEO**

CEO Søren Bregenholt reported on the company's operations. The shareholders were given the opportunity to ask questions regarding the report.

**8. PRESENTATION OF THE ANNUAL REPORT AND AUDIT REPORT AND THE CONSOLIDATED ANNUAL REPORT AND CONSOLIDATED AUDIT REPORT AS WELL AS THE STATEMENT BY THE AUDITOR ON THE COMPLIANCE OF THE APPLICABLE GUIDELINES FOR REMUNERATION TO SENIOR EXECUTIVES**

The Annual Report and the Audit Report, the Consolidated Annual Report and the Consolidated Audit Report for the financial year 2025 as well as the statement by the auditor in accordance with Chapter 8, Section 54 of the Swedish Companies Act on whether the guidelines adopted by the annual general meeting regarding remuneration to the senior executives have been complied with, were presented.

In connection with the presentation of the accounting documents, Ola Bjärehäll from Öhrlings PricewaterhouseCoopers AB reported on the work of the auditors.

**9. RESOLUTION ON**

**(A) ADOPTION OF THE PROFIT AND LOSS STATEMENT AND BALANCE SHEET, AS WELL AS THE CONSOLIDATED PROFIT AND LOSS STATEMENT AND THE CONSOLIDATED BALANCE SHEET**

It was resolved to adopt the profit and loss statement and the balance sheet, as well as the consolidated profit and loss statement and the consolidated balance sheet, as stated in the above presented Annual Report and Consolidated Annual Report.

**(B) DISTRIBUTION OF THE COMPANY'S RESULT ACCORDING TO THE ADOPTED BALANCE SHEET**

It was resolved, in accordance with the proposal from the board of directors in the Annual Report, that no dividends are to be paid for the financial year 2025 and that the accumulated loss shall be carried forward to a new account.

**(C) DISCHARGE FROM LIABILITY OF THE BOARD MEMBERS AND THE CEO**

It was resolved to discharge the board members and the CEO from liability for the financial year 2025.

It was noted that the board members and the CEO did not participate in the resolution regarding own discharge from liability.

**10. DETERMINATION OF THE NUMBER OF BOARD MEMBERS AS WELL AS AUDITORS AND DEPUTY AUDITORS**

The representative of the Nomination Committee, Hans-Peter Ostler, presented the work of the Nomination Committee and the Nomination Committee's proposals for the meeting.

It was resolved in accordance with the proposal from the Nomination Committee that the board of directors shall be composed of four ordinary board members elected by the general meeting.

Furthermore, it was resolved in accordance with the proposal from the Nomination Committee that one registered public accounting firm shall be appointed as auditor until the end of the next annual general meeting.

**11. DETERMINATION OF REMUNERATION FOR THE BOARD MEMBERS AND THE AUDITORS**

It was resolved in accordance with the proposal from the Nomination Committee that board remuneration shall be paid with SEK 650,000 to the Chairman of the board of directors, and with SEK 300,000 to each of the other board members who are not employed by the company. It was further resolved that remuneration for committee work shall be paid with SEK 125,000 to the Chairman of the Audit Committee, with SEK 50,000 to each of the other members of the Audit Committee and with SEK 50,000 to the Chairman of the Remuneration Committee and with SEK 25,000 to each of the other members of the Remuneration Committee.

Finally, it was resolved in accordance with the proposal from the Nomination Committee that remuneration to the auditor shall be paid in accordance with customary norms and approved invoice.

**12. ELECTION OF BOARD MEMBERS, CHAIRMAN OF THE BOARD OF DIRECTORS AS WELL AS AUDITORS AND DEPUTY AUDITORS**

The Chairman of the meeting noted that information on the proposed members of the board and their assignments can be found in the Annual Report and on the company's website, and regarding information about Anna Törner and Jörg Möller in the Nomination Committee's complete proposal.

It was resolved in accordance with the proposal from the Nomination Committee to re-elect Hans-Peter Ostler and Denise Goode as ordinary board members and to elect Anna Törner and Jörg Möller as new ordinary board members. It was furthermore resolved to re-elect Hans-Peter Ostler as Chairman of the board. It was noted that the current board member Eva Sjökvist Saers had declined re-election.

Finally, it was resolved in accordance with the proposal from the Nomination Committee to re-elect Öhrlings PricewaterhouseCoopers AB as auditor. It was noted that Öhrlings PricewaterhouseCoopers AB had informed that Ola Bjärehäll will continue to be the auditor in charge.

**13. RESOLUTION ON APPROVAL OF REMUNERATION REPORT**

The remuneration report for the financial year 2025 was presented in accordance with **Schedule 3**.

It was thereafter resolved to approve the remuneration report for the financial year 2025 in accordance with the proposal in Schedule 3.

**14. RESOLUTION ON AUTHORIZATION REGARDING ISSUES**

The Chairman of the meeting presented the proposal from the board of directors on authorization for the board of directors to resolve on issues in accordance with **Schedule 4**.

It was thereafter resolved to authorize the board of directors to resolve on issues in accordance with the proposal in Schedule 4. It was noted that the resolution was supported by shareholders representing more than two thirds of the votes cast as well as of all shares represented at the meeting.

**15. CLOSING OF THE MEETING**

The Chairman of the meeting declared the meeting closed.

---

In fidem:

Confirmed by:

Ola Grahn  
(Chairman of the meeting)

Anna Stéen

Claes Åkerblad



## NOTICE OF ANNUAL GENERAL MEETING IN ALLIGATOR BIOSCIENCE AB

*The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.*

**The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the annual general meeting to be held on Wednesday 6 May 2026, at 10.00 a.m CEST at Medicon Village, conference room Bengt, Scheelevägen 4 in Lund, Sweden.**

### RIGHT TO PARTICIPATE

Shareholders that want to participate in the annual general meeting must be recorded in the company's share register kept by Euroclear Sweden AB as of Monday 27 April 2026 and, further, have given notice of their intent to participate to the company no later than on Wednesday 29 April 2026, by mail to address, Alligator Bioscience AB, att Greta Höög, Medicon Village, Scheeletorget 1, SE-223 81 Lund, Sweden, by phone to +46 (0)46-540 82 00, or by e-mail to [anmalan@alligatorbioscience.com](mailto:anmalan@alligatorbioscience.com). The notice should specify the shareholder's name, personal identity number or company registration number, telephone number during work hours and the number of shares held by the shareholder and, when applicable, information on the number of advisors (2 at the most).

### TRUSTEE-REGISTERED SHARES

Shareholders whose shares are trustee-registered in the name of a bank or other trustee must, to be able to exercise their voting rights at the general meeting, request the trustee to register their shares in their own name with Euroclear Sweden AB (so called "voting rights registration"). Such voting rights registration must be implemented by the trustee no later than as of Wednesday 29 April 2026. Accordingly, shareholders must well in advance before this date notify their trustee of their request of such voting rights registration.

### PROXY

Shareholders participating by proxy must issue a dated and signed proxy. Should the proxy be issued by a legal entity, a certified copy of the valid registration certificate (Sw. registreringsbevis) of the legal entity (or corresponding document) must be presented. Proxies should be in writing and submitted at the latest at the annual general meeting, but should preferably be sent before the general meeting. The validity term of the proxy may be at the longest five years if this is specifically stated. In case no validity term is stated, the proxy is valid for at the longest one year. Proxy forms are available at the company's website ([www.alligatorbioscience.com](http://www.alligatorbioscience.com)) and at the company (see address above), and will also be sent to the shareholders that request it and state their address.

## **PROPOSED AGENDA**

1. Opening of the meeting
2. Election of Chairman of the meeting
3. Preparation and approval of the register of voters
4. Election of two persons to confirm the minutes
5. Approval of the agenda
6. Determination as to whether the meeting has been duly convened
7. Presentation by the CEO
8. Presentation of the Annual Report and Audit Report and the Consolidated Annual Report and Consolidated Audit Report as well as the statement by the auditor on the compliance of the applicable guidelines for remuneration to senior executives
9. Resolution on
  - a) adoption of the profit and loss statement and balance sheet, as well as the consolidated profit and loss statement and the consolidated balance sheet;
  - b) distribution of the company's result according to the adopted balance sheet; and
  - c) discharge from liability of the board members and the CEO
10. Determination of the number of board members as well as auditors and deputy auditors
11. Determination of remuneration for the board members and the auditors
12. Election of board members, Chairman of the board of directors as well as auditors and deputy auditors
13. Resolution on approval of remuneration report
14. Resolution on authorization regarding issues
15. Closing of the meeting

## **PROPOSED RESOLUTIONS**

### ***Item 2: Election of Chairman of the meeting***

The Nomination Committee, consisting of Lars Bergkvist (Chairman), representing Roxette Photo SA, Jan Lundström, representing Johan Zetterstedt, Johan Ranstam, representing AB Gryningsstunden Förvaltning, and the Chairman of the board of directors, Hans-Peter Ostler, proposes that lawyer Ola Grahn is elected as Chairman of the annual general meeting or, in his absence, the person appointed by the Nomination Committee instead.

### ***Item 9 b: Resolution on distribution of the company's result***

The board of directors proposes that no dividends are paid and that the accumulated loss of SEK -83,280,054 shall be carried forward to a new account.

***Item 10: Determination of the number of board members as well as auditors and deputy auditors***

The Nomination Committee proposes that the board of directors shall consist of four ordinary board members elected by the annual general meeting.

Furthermore, the Nomination Committee proposes, in accordance with the recommendation from the Audit Committee, that one registered public accounting firm without deputy is appointed.

***Item 11: Determination of remuneration for the board members and the auditors***

The Nomination Committee proposes that the board remuneration and the remuneration for committee work is unchanged compared to the year 2025; meaning SEK 650,000 to the Chairman of the board of directors and SEK 300,000 to each of the other board members who are not employed by the company. Furthermore, remuneration for committee work is proposed to be SEK 125,000 to the Chairman of the Audit Committee, SEK 50,000 to each of the other members of the Audit Committee, and SEK 50,000 to the Chairman of the Remuneration Committee and SEK 25,000 to each of the other members of the Remuneration Committee.

Furthermore, the Nomination Committee proposes that remuneration for the auditor shall be paid in accordance with customary norms and approved invoice.

***Item 12: Election of board members, Chairman of the board of directors as well as auditors and deputy auditors***

The Nomination Committee proposes that Hans-Peter Ostler and Denise Goode are re-elected as board members and that Anna Törner and Jörg Möller are elected as new board members. The Nomination Committee also proposes that Hans-Peter Ostler is re-elected as Chairman of the board of directors. Eva Sjökvist Saers has declined re-election.

**Anna Törner**, born in 1963 has extensive experience from the pharmaceutical industry, academic research, and regulatory authorities, with deep expertise in regulatory strategy and phase 2/3 study design. She is the founder and former CEO of SDS Life Science, previously a leading drug development consultancy in the Nordics.

*Education:* MSc Pharmacy and MSc Mathematical Statistics and PhD Medical Science (statistics) from Karolinska Institutet.

*Other ongoing assignments:* Chairman of the Board in Arendi AB and Lett Renovering AB. Board member of Medivir Aktiebolag, MedCap AB (publ), Attgeno AB, Akiram Therapeutics AB and Jonas & Kollegor AB. CEO and Board member of At Statistics AB.

*Shareholding in Alligator Bioscience AB: -*

Anna Törner is considered independent in relation to both the company and its management as well as in relation to major shareholders.

**Jörg Möller**, born in 1964, has more than 30 years of experience in pharmaceuticals and biotech R&D, including leading global research and development at Bayer AG and Leo Pharma A/S. He has also held CEO and various board roles in various biotech companies such as Antag Therapeutics ApS, Benevolent AI, Casebia Therapeutics LLP and Bluerock Therapeutics LP.

*Education:* Jörg Möller holds a medical degree and a PhD from the Ruhr University Bochum Medical School in Germany.

*Other ongoing assignments:* Board member in Secura Bio Inc.

*Shareholding in Alligator Bioscience AB: -*

Jörg Möller is considered independent in relation to both the company and its management as well as in relation to major shareholders.

Information on the board members proposed for re-election can be found at the company's website and in the Annual Report (see [www.alligatorbioscience.com](http://www.alligatorbioscience.com)).

Furthermore, the Nomination Committee proposes, in accordance with the recommendation from the Audit Committee, that the registered accounting firm Öhrlings PricewaterhouseCoopers AB (PwC) is re-elected as auditor. PwC has informed that the authorized public accountant Ola Bjärehäll will continue to be appointed as the responsible auditor.

### ***Item 13: Resolution on approval of remuneration report***

The board of directors proposes that the annual general meeting resolves to approve the board of directors' remuneration report for the financial year 2025.

### ***Item 14: Resolution on authorization regarding issues***

The board of directors proposes that the annual general meeting resolves to authorize the board of directors, up until the next annual general meeting, at one or several occasions, with or without deviation from the shareholders' preferential rights and with or without provisions regarding contribution in kind, set-off or other conditions, to resolve to issue new ordinary shares, convertibles and/or warrants with right to convert into and subscribe for ordinary shares respectively. The reason for why a deviation from the shareholders' preferential rights should be possible is to enable the company to be able to source working capital, to be able to extend the ownership base with one of more owners of strategic importance, to be able to execute acquisitions of companies or operating assets as well as to enable new issues to industrial partners within the framework of partnerships and alliances. The

**PRESS RELEASE**

30 March 2026 08:45:00 CEST



total number of ordinary shares that may be issued (alternatively be issued through conversion of convertibles and/or exercise of warrants) shall not exceed 20 per cent of the number of outstanding ordinary shares as per the date when the issue authorization is utilized for the first time.

In case the authorization is used for an issue with deviation from the shareholders' preferential rights, the issue shall be made on market terms.

The company's CEO shall be authorized to make the minor formal adjustments of the resolution which may be required for registration with the Swedish Companies Registration Office (Sw. Bolagsverket).

**PARTICULAR MAJORITY REQUIREMENTS**

For a valid resolution on the proposal pursuant to item 14, the proposal has to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the annual general meeting.

**GENERAL MEETING DOCUMENTS AND OTHER INFORMATION**

Accounting documents, the audit report, the board of directors' remuneration report, the statement by the auditor on the compliance of the applicable guidelines for remuneration to senior executives, the complete proposals for resolutions and other documents for the general meeting will be kept available at the company's office at Medicon Village, Scheeleorget 1, SE-223 81 Lund, Sweden and at the company's website ([www.alligatorbioscience.com](http://www.alligatorbioscience.com)) as from no later than three weeks prior to the general meeting. Copies of documents will be sent to shareholders who request it and provide their address and will also be available at the annual general meeting.

At the annual general meeting, the board of directors and the CEO shall, if any shareholder so requests and the board of directors believes that it can be done without significant harm to the company, provide information regarding circumstances that may affect the assessment of items on the agenda, circumstances that can affect the assessment of the company's or its subsidiaries' financial position and the company's relation to other companies within the group.

As per the date of the notice, the total number of shares and votes in the company amounts to 628,106,848, of which all outstanding shares are ordinary shares.

**PROCESSING OF PERSONAL DATA**

For information on how your personal data is processed, see <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>.

**PRESS RELEASE**

30 March 2026 08:45:00 CEST



---

Lund in March 2026

ALLIGATOR BIOSCIENCE AB (PUBL)

The Board of Directors

**Attachments**

---

**[Notice of annual general meeting in Alligator Bioscience AB](#)**



2025

**Remuneration report 2025**  
Alligator Bioscience AB (publ)

This is a translation of the Swedish language original. In the event of any differences between this translation and the Swedish language original, the latter shall prevail.

# Remuneration report 2025

## Introduction

This remuneration report describes how the guidelines for remuneration to senior executives of Alligator Bioscience AB ("**Alligator**"), adopted by the extraordinary general meeting in March 2025, were implemented in 2025. The report also provides information on remuneration to the CEO and a summary of Alligator's outstanding share-related and share price-related incentive programs. The report has been prepared in accordance with the Swedish Companies Act and the Remuneration Rules issued by the Stock Market Self-Regulation Committee.

Further information on remuneration to senior executives is available in note 12 (Payments to senior executives) on pages 87-89 in the annual report 2025. Information on the work of the Remuneration Committee in 2023 is set out in the corporate governance report available on pages 53-61 in the annual report 2025.

Remuneration of the board of directors is not covered by this report. Such remuneration is resolved annually by the annual general meeting and disclosed in note 12 on pages 87-89 in the annual report 2025.

## Developments during 2025

The CEO summarizes the company's overall performance in his statement on pages 6-8 in the annual report 2025.

## The company's remuneration guidelines: scope, purpose and deviations

A prerequisite for the successful implementation of Alligator's business strategy and safeguarding of

its long-term interests, including its sustainability, is that the company can recruit and retain qualified personnel. To this end, the company must offer competitive remuneration on market terms. The Alligator's remuneration guidelines enable the company to offer executives a competitive total remuneration on market terms. According to the remuneration guidelines, remuneration to senior executives may consist of the following components: fixed salary, variable cash remuneration, pension benefits and other benefits. The variable cash remuneration shall be linked to financial or non-financial criteria. They may be individualized quantitative or qualitative objectives. The criteria shall be designed to contribute to Alligator's business strategy and long-term interests, including its sustainability, by for example being clearly linked to the business strategy or promote the executive's long-term development.

The guidelines are found on pages 40-42 in the annual report 2025. During 2025, Alligator has complied with the applicable remuneration guidelines adopted by the general meeting. No deviations from the guidelines have been made and no derogations from the procedure for implementation of the guidelines have been made. The auditor's report regarding Alligator's compliance with the guidelines is available on Alligator's website, [www.alligatorbioscience.se/en/corporate-governance/general-meeting/](http://www.alligatorbioscience.se/en/corporate-governance/general-meeting/).

No remuneration has been reclaimed. In addition to remuneration covered by the remuneration guidelines, the general meetings of Alligator have resolved to implement long-term share-related incentive programs.

**Table 1 – Total remuneration to the CEO in 2025 (KSEK)\***

	1		2		3	4	5	6
	Fixed remuneration		Variable remuneration					
Name of director (position)	Base salary <sup>1)</sup>	Other benefits <sup>2)</sup>	One-year variable	Multi-year variable	Extraordinary items	Pension expense <sup>3)</sup>	Total remuneration	Proportion of fixed and variable remuneration
Søren Bregenholt (CEO)	4,166	144	767	-	-	566	5,633	86/14

\* Except for Multi-year variable remuneration, the table reports remuneration earned in 2025.

<sup>1)</sup> Including holiday pay.

<sup>2)</sup> Refers to car benefit, benefit for fuel and congestion tax.

<sup>3)</sup> Pension expense (column 4), which in its entirety relates to Base salary and is premium defined, has been accounted entirely as fixed remuneration.

## Share-based remuneration

Alligator has issued warrants under two warrant programs covering employees of Alligator and two warrant programs covering certain members of the board of directors. The information below reflects the adjusted terms of the warrant programs following rights issues carried out during 2024 and early 2025, as well as a reverse share split of ordinary shares implemented in 2025. Further adjustments will be made as a result of the rights issue conducted by Alligator in December 2025.

### Outstanding share-related and share price-related incentive programs

#### Warrant program LTI 2023 I/II

The Annual General Meeting held 2023 resolved to implement a warrant program for employees and certain board members (“**LTI 2023 I**” and “**LTI 2023 II**”, respectively). Due to completed rights issues during 2024 and 2025, as well as the reverse share split of ordinary shares, the subscription price per ordinary share for the above warrants has been recalculated to SEK 32.03. Each warrant entitles the holder to subscribe for 0.0331 ordinary shares. If all warrants LTI 2023 I/II are exercised a total of 209,468 new ordinary shares will be issued, which corresponds to a dilution of approximately 1.2% as of 31 December 2025. Additional recalculation will be made post exercise of TO 13 and the rights issue in December 2025. All warrants have been transferred to the participants at fair market value. In LTI 2023-I, CEO Søren Bregenholt has acquired a total of 1,200 warrants at fair market value.

The warrants in LTI 2023 I/II can be utilized for subscription of new ordinary shares in Alligator during the period 1–30 June 2026.

#### Warrant program LTI 2024 I/II

The Annual General Meeting held 2024 resolved to implement a warrant program for employees and certain board members (“**LTI 2024 I**” and “**LTI 2024 II**”,

respectively). After recalculation due to completed rights issue during 2025 the subscription price has been recalculated to SEK 51.11 per share. Each warrant is entitled to 0.0331 shares. If all warrants LTI 2024 I/II are exercised a total of 105,727 new ordinary shares will be issued, which corresponds to a dilution of approximately 0.6% as of 31 December 2025. Additional recalculation will be made post exercise of TO 13 and the rights issue in December 2025. All warrants have been transferred to the participants at fair market value. In LTI 2024 I, CEO Søren Bregenholt has acquired a total of 900 warrants at fair market value.

The warrants in LTI 2024 I/II can be utilized for subscription of new ordinary shares in Alligator during the period 1–30 June 2027.

Further information on Alligator’s outstanding incentive programs is available in Note 27 (Equity) on page 97 in the 2025 annual report.

### Expired share-based and share price-related warrant programs during 2025

#### Warrant program LTI 2022 I/II

The Annual General Meeting held 2022 resolved to implement a warrant program for employees and certain board members (“**LTI 2022 I**” and “**LTI 2022 II**”, respectively). The warrant programs LTI 2022 I/II expired in June 2025 without exercise, and no ordinary shares were issued.

### Application of performance criteria

The performance criteria for the CEO’s variable remuneration have been selected to deliver the company’s strategy and to encourage behavior which is in the long-term interest of Alligator. In the selection of performance criteria, the strategic objectives and short-term and long-term business priorities for 2025 have been taken into account. The non-financial performance measures further contribute to alignment with sustainability as well as Alligator’s values.

**Table 2 – Performance of the CEO in the reported financial year: variable cash remuneration**

	1	2	3
Name of director (position)	Description of the criteria related to the remuneration component	Relative weighting of the performance criteria	a) Measured performance; and b) actual award / remuneration outcome
Søren Bregenholt (CEO)	Financing/partner agreements	50%	a) 15% b) 177 KSEK
	Development of/progress in the clinical programs	50%	a) 50% b) 590 KSEK

## Comparative information on the change of remuneration and Alligator's performance

**Table 3 – Change of remuneration and Alligator's performance over the last five reported financial years (FY) (KSEK)**

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
CEO remuneration	5,633	5,243	5 202	4,399	6,330 <sup>1)</sup>
Group operating profit	-105,826	-229,141	-248,983	-192,789	-141,565
Average remuneration on a full time equivalent basis of employees <sup>2)</sup> of the parent company	1,384	913	916	943	780

<sup>1)</sup> CEO remuneration during the financial year 2021 includes remuneration to the current CEO Søren Bregenholt as well as the former acting CEO Malin Carlsson and the former CEO Per Norlén (including severance pay).

<sup>2)</sup> Excluding members of the group executive management.

---

Lund in March 2026

The Board of Directors of Alligator Bioscience AB (publ)





*The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.*

## **PROPOSAL FOR RESOLUTION ON AUTHORIZATION REGARDING ISSUES**

The board of directors of Alligator Bioscience AB, Reg. No. 556597-8201, proposes that the annual general meeting on 6 May 2026 resolves to authorize the board of directors, up until the next annual general meeting, at one or several occasions, with or without deviation from the shareholders' preferential rights and with or without provisions regarding contribution in kind, set-off or other conditions, to resolve to issue new ordinary shares, convertibles and/or warrants with right to convert into and subscribe for ordinary shares respectively. The reason for why a deviation from the shareholders' preferential rights should be possible is to enable the company to be able to source working capital, to be able to extend the ownership base with one of more owners of strategic importance, to be able to execute acquisitions of companies or operating assets as well as to enable new issues to industrial partners within the framework of partnerships and alliances. The total number of ordinary shares that may be issued (alternatively be issued through conversion of convertibles and/or exercise of warrants) shall not exceed 20 per cent of the number of outstanding ordinary shares as per the date when the issue authorization is utilized for the first time.

In case the authorization is used for an issue with deviation from the shareholders' preferential rights, the issue shall be made on market terms.

---

For a valid resolution, the proposal has to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the annual general meeting.

The company's CEO shall be authorized to make the minor formal adjustments of the resolution which may be required for registration with the Swedish Companies Registration Office (Sw. Bolagsverket).

---

Lund in March 2026

The board of directors of Alligator Bioscience AB (publ)